SC
NVAX icon

Stance Capital’s Novavax NVAX Stock Holding History

Stance Capital’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.07K Buy
+500
New +$4.53K ﹤0.01% 267
2025
Q4 		– Sell
-500
Closed -$4.33K – 244
2025
Q3 		$4.33K Buy
+500
New +$3.89K ﹤0.01% 266
2025
Q1 		– Sell
-500
Closed -$4.02K – 200
2024
Q4 		$4.02K Buy
+500
New +$4.82K ﹤0.01% 192

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stance Capital's NVAX Position: Q1 2026 in Review

Stance Capital opened a new position in Novavax (NVAX) in Q1 2026: 500 shares worth $4.07K. The stake represents ﹤0.01% of the portfolio and ranks #267 among its holdings. This is a return to the name: Stance Capital previously reported a position in NVAX as recently as Q3 2025.

Stance Capital first reported a position in NVAX in Q4 2024 and has held it in 3 quarters since. The position peaked at $4.33K in Q3 2025. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • Stance Capital held 500 shares of Novavax worth $4.07K as of Q1 2026.
  • Novavax was a new Stance Capital position in Q1 2026.
  • Novavax made up ﹤0.01% of Stance Capital's portfolio in Q1 2026, its #267 holding.
  • Stance Capital first reported a position in Novavax in Q4 2024 and has held it in 3 quarters since.
  • Stance Capital's Novavax position peaked at $4.33K in Q3 2025.
  • 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Stance Capital's 13F filing for Q1 2026, filed 14 May 2026.